Knowledge of metabolism, enzymes so far involved, and potential enzyme-inhibiting or enzyme-inducing properties of new compounds is a key issue in drug development. Primary cultured hepatocytes, cytochrome P450 (CYP)-engineered cells and hepatoma cell lines are currently being used for this purpose, but only primary cultures can produce a metabolic profile of a drug similar to that found in vivo and can respond to inducers. Because of their limited accessibility, alternatives to replace human hepatocytes are currently being explored, including the immortalisation of hepatocytes by using different strategies (i.e. SV40 T-large antigen, conditionally immortalised hepatocytes, transfection with c-myc, cH-ras, N-ras oncogenes, transgenic animals over-expressing growth factors or oncogenes and cre-lox recombination/excision). However, none of the resulting cells has the desirable phenotypic characteristics to replace primary cultures in drug metabolisms studies. We investigated why these differentiated human hepatomas do not express CYP genes and found that the levels of certain key transcription factors clearly differ from those found in hepatocytes. It was then conceivable that re-expression of one (or more) of these transcription factors could lead to an efficient transcription of CYP genes. The feasibility of this hypothesis was demonstrated by genetic engineering of Hep G2 cells with liver-enriched transcription factors followed by the analysis of the expression of the most relevant human CYPs.
FischbachM., CaoH., IbañezM.D., TsaconasS., AlouaniS., MontandonF., el BarakaM., PadieuP., DreanoM., & Chessebeuf-PasdieuM. (1991). Maintenance of liver function in long-term culture of hepatocytes following in vitro or in vivo Ha-ras transfection. Cell Biology and Toxicology7, 327–345.
2.
BayadJ., BagrelD., SabolovicN., MagdalouJ., & SiestG. (1991). Expression and regulation of drug metabolizing enzymes in an immortalized rat hepatocyte cell line. Biochemical Pharmacology12, 1345–1351.
3.
IsomH.C., WoodworthC.D., MengY., KreiderJ., MillerT., & MengelL. (1992). Introduction of the ras oncogene transforms a simian virus 40-immortalized hepatocyte cell line without loss of expression of albumin and other liver-specific genes. Cancer Research52, 940–948.
4.
AndersonK., YinL.M., MacDonaldC., & GrantM.H. (1996). Immortalized hepatocytes as in vitro model systems for toxicity testing: the comparative toxicity of menadione in immortalized cells, primary cultures of hepatocytes and HTC hepatoma cells. Toxicology in Vitro10, 721–727.
5.
OurlinJ.C., VilaremM.J., DaujautM., HarricaneM.C., DomergueJ., JoyeuxH., BaulieuxJ., & MaurelP. (1997). Lipid-mediated transfection of normal adult human hepatocytes in primary culture. Analytical Biochemistry247, 34–44.
6.
JoverR., BortR., Gómez-LechónM.J., & CastellJ.V. (2000). Using hepatic cell lines for drug metabolism studies? In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. BallsM., van ZellerA-M., & HalderM.E.), pp. 127–137. Amsterdam, The Netherlands: Elsevier Science B.V.
YanaiN., SuzukiM., & ObinataM. (1991). Hepatocyte cell lines established from transgenic mice harboring temperature-sensitive simian virus 40 large T antigen gene. Experimental Cell Research197, 50–56.
9.
WuJ.C., MerlinoG., CveklovaK., MosingerB., & FaustoN. (1994). Autonomous growth in serum-free medium production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. Cancer Research54, 5964–5973.
10.
AmiconeL., SpagnoliF.M., SpathG., GiordanoS., TommasiniC., BernardiniS., De LucaV., Della RoccaC., WeissM.C., ComoglioP.M., & TripodiM. (1997). Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO Journal16, 495–503.
11.
BuleraS.J., HaasM.J., SattlerC.A., & PitotH.C. (1997). Cell lines with heterogenous phenotypes from a single isolation of albumin-SV40 T-antigen transgenic rat hepatocytes. Hepatology25, 1192–1203.
12.
Courjault-GautierF., AntoineB., BensM., ValletV., CluzeaudF., PringaultE., KhanA., ToutainH., & VandewalleA. (1997). Activity and inducibility of drug-metabolizing enzymes in immortalized hepatocyte-like cells (mhPKT) derived from a L-PK/Tag1 transgenic mouse. Experimental Cell Research234, 362–372.
13.
DonatoM.T., KlockeR., CastellJ.V., StenzelK., PaulD., & Gómez-LechónM.J. (2003). Constitutive and inducible expression of CYP isozymes in immortal hepatocytes derived from SV40 transgenic mice. Xenobiotica33, 459–473.
14.
KlockeR., Gómez-LechónM.J., EhrhardtA., Mendoza-FigueroaT., DonatoT., López-RevillaR., CastellJ.V., & PaulD. (2002). Establishment and characterization of immortal hepatocytes derived from various transgenic mouse lines. Biochemical and Biophysical Research Communications294, 864–871.
15.
Rodríguez-AntonaC., DonatoM.T., BoobisA., EdwardsR.J., WattsP.S., CastellJ.V., & Gómez-LechónM.J. (2002). Cytochrome P-450 expression in human hepatocytes and human hepatoma cell lines. Molecular mechanisms that determine the lower expression in cultured cells. Xenobiotica32, 505–520.
16.
DonatoM.T., BassiA.M., Gómez-LechónM.J., PencoS., HerreroE., AdamoD., CastellJ.V., & FerroM. (1994). Evaluation of the xenobiotic biotransformation capability of six rodent hepatoma cell lines in comparison with rat hepatocytes. In Vitro Cellular and Developmental Biology30A, 574–580.
17.
Gómez-LechónM.J., DonatoT., JoverR., RodriguezC., PonsodaX., GlaiseD., CastellJ.V., & Guguen-GuillouzoC. (2001). Expression and induction of a large set of drug metabolism enzymes by the highly differentiated human hepatoma cell line BC2. European Journal of Biochemistry268, 1448–1459.
18.
Rodriguez-AntonaC., JoverR., Gómez-LechónM.J., & CastellJ.V. (2000). Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Archives of Biochemistry and Biophysics375, 1–8.
JoverR., BortR., Gómez-LechónM.J., & CastellJ.V. (1998). Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in Hep G2 cells. FEBS Letters431, 227–230.
21.
CastellJ.V., HernandezD., Gomez-FoixA.M., GuillenI., DonatoT., & Gómez-LechónM.J. (1997). Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Therapy4, 455–464.
22.
Rodriguez-AntonaC., BortR., JoverR., TindbergN., Ingelman-SundbergM., Gómez-LechónM.J., & CastellJ.V. (2002). Transcriptional regulation of human CYP3A4 expression by C/EBPα and HNF3γ. Molecular Pharmacology63, 1180–1189.
23.
LaiE., ClarkK., BurleyS., & DarnellJ. (1993). Hepatocyte nuclear factor 3/fork head or “winged helix” proteins: a family of transcription factors of diverse biologic function. Proceedings of the National Academy of Sciences USA90, 10421–10423.
24.
KaestnerK., HiemischH., & SchutzG. (1998). Targeted disruption of the gene encoding hepatocyte nuclear factor 3gamma results in reduced transcription of hepatocyte-specific genes. Molecular and Cellular Biology18, 4245–4251.
25.
CroweA., SangL., LiK., LeeK., SpearB., & BartonM. (1999). Hepatocyte nuclear factor 3 relieves chromatin-mediated repression of the alpha-fetoprotein gene. Journal of Biological Chemistry274, 25113–25120.
26.
DonatoT., JoverR., PonsodaX., CastellJ., & Gómez-LechónM. (2002). In vitro hepatic models for drug metabolism studies and human cytochrome P450 characterization. Recent Research in Developmental Drug Metabolism and Disposition1, 83–100.
27.
MangelsdorfD., ThummelC., BeatoM., HerrlichP., SchutzG., UmesonoK., BlumbergB., KastnerP., MarkM., ChambonP. (1995). The nuclear receptor superfamily: the second decade. Review83, 835–839.
28.
HertzR., MagenheimJ., BermanI., & BarT.J. (1998). Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4alpha. Nature, London392, 512–516.
29.
SladekF., ZhongW., LaiE., & DarnellJ.J. (1990). Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes and Development12B, 2353–2365.
30.
JiangG., NepomucenoL., HopkinsK., & SladekF. (1995). Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. Molecular and Cellular Biology9, 5131–5143.
31.
YamagataK., FurutaH., OdaN., KaisakiP., MenzelS., CoxN., FajansS., SignoriniS., StoffelM., & BellG. (1996). Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature, London384, 458–460.
32.
Hadzopoulou-CladarasM., KistanovaE., EvagelopoulouC., ZengS., CladarasC., & LadiasJ. (1997). Functional domains of the nuclear receptor hepatocyte nuclear factor 4. Journal of Biological Chemistry1, 539–550.
33.
JoverR., BortR., Gómez-LechónM.J., & CastellJ.V. (2001). Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adrenovirus-mediated antisense targeting. Hepatology33, 668–675.
34.
NakheiH., LingottA., LemmI., & RyffelG. (1998). An alternative splice variant of the tissue specific transcription factor HNF4alpha predominates in undifferentiated murine cell types. Nucleic Acids Research2, 497–504.
35.
ChartierF., BossuJ., LaudetV., FruchartJ., & LaineB. (1994). Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. Gene2, 269–272.
36.
HataS., TsukamotoT., & OsumiT. (1992). A novel isoform of rat hepatocyte nuclear factor 4 (HNF-4). Biochimica et Biophysica Acta1131, 211–213.
37.
HataS., InoueT., KosugaK., NakashimaT., TsukamotoT., & OsumiT. (1995). Identification of two splice isoforms of mRNA for mouse hepatocyte nuclear factor 4 (HNF-4). International Journal of Peptide and Protein Research2, 106–112.
38.
DrewesT., SenkelS., HolewaB., & RyffelG. (1996). Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Molecular and Cellular Biology3, 925–931.
39.
FurutaH., IwasakiN., OdaN., HinokioY., HorikawaY., YamagataK., YanoN., SugahiroJ., OgataM., OhgawaraH., OmoriY., IwamotoY., & BellG. (1997). Organization and partial sequence of the hepatocyte nuclear factor-4 alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY. Diabetes46, 1652–1657.
40.
Torres-PadillaM., Fougere-DeschatretteC., & WeissM. (2001). Expression of HNF4alpha isoforms in mouse liver development is regulated by sequential promoter usage and constitutive 3′ end splicing. Mechanisms of Development2, 183–193.
41.
KimuraA., NishiyoriA., MurakamiT., TsukamotoT., HataS., OsumiT., OkamuraR., MoriM., & TakiguchiM. (1993). Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) represses transcription from the promoter of the gene for ornithine transcarbamylase in a manner antagonistic to hepatocyte nuclear factor-4 (HNF-4). Journal of Biological Chemistry268, 11125–11133.
42.
KtistakiE., & TalianidisI. (1997). Modulation of hepatic gene expression by hepatocyte nuclear factor 1. Science, New York277, 109–112.
43.
MiyajimaN., KadowakiY., FukushigeS., ShimizuS., SembaK., YamanashiY., MatsubaraK., ToyoshimaK., & YamamotoT. (1988). Identification of two novel members of erbA superfamily by molecular cloning: the gene products of the two are highly related to each other. Nucleic Acids Research16, 11057–11074.
44.
DescombesP., & SchiblerU. (1991). A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell67, 569–579.
45.
OssipowV., DescombesP., & SchiblerU. (1993). CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proceedings of the National Academy of Sciences USA90, 8219–8223.
46.
WelmA., MackeyS., TimchenkoL., DarlingtonG., & TimchenkoN. (2000). Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/enhancer binding protein alpha mRNA. Journal of Biological Chemistry275, 27406–27413.
47.
ZahnowC., YounesP., LauciricR., & RosenJ. (1997). Overexpression of C/EBPbeta-LIP, a naturally occurring dominant-negative transcription factor, in human breast cancer. Journal of the National Cancer Institute89, 1887–1891.
48.
TrautweinC., RakemannT., PietrangeloA., PlumpeJ., MontosiG., & MannsM. (1996). C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration. Journal of Biological Chemistry271, 22262–22270.
49.
JoverR., BortR., Gómez-LechónM.J., & CastellJ. (2002). Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB Journal16, 1799–1801.
50.
RonD., & HabenerJ. (1992). CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes and Development6, 439–453.
51.
TangQ., & LaneM. (2000). Role of C/EBP homologous protein (CHOP-10) in the programmed activation of CCAAT/enhancer-binding protein-beta during adipogenesis. Proceedings of the National Academy of Sciences USA97, 12446–12450.
52.
RazinA., & RiggsA. (1980). DNA methylation and gene function. Science210, 604–610.
53.
JonesP., VeenstraG., WadeP., VermaakD., KassS., LandsbergerN., StrouboulisJ., & WolffeA. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics19, 187–191.
54.
NanX., NgH., JohnsonC., LahertyC., TurnerB., EisenmanR., & BirdA. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, London393, 386–389.
55.
CollingwoodT., UrnovF., & WolffeA. (1999). Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. Journal of Molecular Endocrinology23, 255–275.
56.
BrownC., LechnerT., HoweL., & WorkmanJ. (2000). The many HATs of transcription coactivators. Trends in Biochemical Sciences25, 15–19.
